Document Detail


In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.
MedLine Citation:
PMID:  23544171     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Treatment for glioblastoma consists of radiotherapy and temozolomide-based chemotherapy. However, virtually all patients recur, leading to a fatal outcome. Receptor tyrosine kinase (RTK)-targeted therapy has been the focus of attention in novel treatment options for these patients. Here, we compared the efficacy of imatinib, sunitinib, and cediranib in glioblastoma models. In the present work, the biologic effect of the drugs was screened by viability, cell cycle, apoptosis, migration, and invasion in vitro assays or in vivo by chick chorioallantoic membrane assay. Intracellular signaling was assessed by Western blot and the RTK targets were identified using phospho-RTK arrays. The amplified status of KIT, PDGFRA, and VEGFR2 genes was assessed by quantitative polymerase chain reaction. In a panel of 10 glioblastoma cell lines, we showed that cediranib was the most potent. In addition, cediranib and sunitinib synergistically sensitize the cells to temozolomide. Cediranib efficacy was shown to associate with higher cytostatic and unique cytotoxic effects in vitro and both antitumoral and antiangiogenic activity in vivo, which could associate with its great capacity to inhibit mitogen-activated protein kinase (MAPK) and AKT pathways. The molecular status of KIT, PDGFRA, and VEGFR2 did not predict glioblastoma cell responsiveness to any of the RTK inhibitors. Importantly, phospho-RTK arrays revealed novel targets for cediranib and sunitinib therapy. In conclusion, the novel targets found may be of value as future biomarkers for therapy response in glioblastoma and lead to the rational selection of patients for effective molecular targeted treatment.
Authors:
Olga Martinho; Renato Silva-Oliveira; Vera Miranda-Gonçalves; Carlos Clara; José Reynaldo Almeida; André Lopes Carvalho; João Taborda Barata; Rui Manuel Reis
Publication Detail:
Type:  Journal Article     Date:  2013-04-01
Journal Detail:
Title:  Translational oncology     Volume:  6     ISSN:  1936-5233     ISO Abbreviation:  Transl Oncol     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-01     Completed Date:  2013-04-02     Revised Date:  2013-04-03    
Medline Journal Info:
Nlm Unique ID:  101472619     Medline TA:  Transl Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  187-96     Citation Subset:  -    
Affiliation:
Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal ; ICVS/3B's, PT Government Associate Laboratory, Braga, Guimarães, Portugal ; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances ...
Next Document:  Notch pathway is activated by MAPK signaling and influences papillary thyroid cancer proliferation.